POTASSIUM ACETATE (potassium acetate) by Pfizer is clinical pharmacology as the principal cation of the intracellular fluid, potassium plays an important role in fluid and electrolyte balance. First approved in 1984.
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
Potassium acetate is an injectable electrolyte replacement therapy that restores intracellular and serum potassium levels while providing an alternate source of bicarbonate through hepatic metabolism of acetate. It is used to treat hypokalemia (low potassium) and maintain electrolyte balance in patients receiving parenteral nutrition or experiencing potassium depletion. The drug works by replacing the principal intracellular cation and supporting acid-base balance through acetate conversion.
As LOE approaches and generic competition intensifies (30% competitive pressure), the brand team is likely consolidating focus on hospital/institutional channels and differentiation strategies rather than expansion.
CLINICAL PHARMACOLOGY As the principal cation of the intracellular fluid, potassium plays an important role in fluid and electrolyte balance. The normal potassium concentration in the intracellular fluid compartment is about 160 mEq/liter. The normal serum potassium range is 3.5 to 5.0 mEq/liter.…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
With zero linked job openings and approaching LOE, career opportunities on potassium acetate are minimal and primarily focused on defending existing market share in institutional channels. This is a maintenance-stage product best suited for professionals with hospital supply chain or institutional account management experience seeking stable, non-growth roles.
Worked on POTASSIUM ACETATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo